Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

This price cut came just days after Eli Lilly reduced the price of its weight-loss drug Zepbound by at least ... with all dose strengths now meeting current and expected U.S. demand.

Like many pharma stocks, Eli Lilly (NYSE: LLY ... loss candidate it's suggested may be even more effective than its current drugs, and orforglipron, a weight loss candidate in pill form.